Collaboration between the Murcian Health Service, the Andalusian Health Service and the Murcian biotechnology company Viva in Vitro in a research project to reduce hospital mortality due to sepsis.
In the rapidly evolving landscape of biotechnology, companies like those recently selected for the EIC Transition are not just pushing scientific boundaries; we are all participating in redefining what it means to be a successful, purpose-driven enterprise in the 21st century.
The Biotech Revolution: Navigating Innovation with Purpose in the Age of Disruption Read More »
The European Innovation Council (EIC) selects Viva in Vitro Diagnostics as one of the 40 most disruptive European companies and awards €2.5 million in non-dilutive funding from the EIC Transition programme.
From Viva in Vitro, in collaboration with Pablo González-Polanco, Product Development Engineer, and Dr. Verónica Cánovas, Biotechnology Development Manager, we have identified the main trends that are transforming the approach to sepsis. Here we share an in-depth analysis of these innovations. Sepsis continues to be one of the leading causes of mortality and morbidity worldwide, affecting both healthcare systems and millions of patients and their families. With nearly 48.9 million cases annually worldwide and 11 million deaths, this condition represents a critical challenge that demands innovative solutions.
Key Trends in Sepsis Treatment for 2025 Read More »
On the program “Entre Probetas” on RNE, Radio 5, our Biotechnology Development Manager, Verónica Cánovas, addressed one of the most critical challenges in biomedicine today: sepsis. This exacerbated immune process can endanger the individual it seeks to protect. Join us for a conversation about research, innovative solutions and the future of biotechnology.
Viva in Vitro has been awarded the Research Award at the Isaac Peral Foundation Awards 2024. This recognition highlights our advance in biotechnology with the development of a pioneering device to detect NLRP3 inflammasome activity in patients with sepsis, contributing to the diagnosis and treatment of this serious disease.
In less than 3 years, the Spanish biotech company has attracted the confidence of investors and international medical institutions to complete the development of its Viva Sepscare® prototype for the rapid detection and stratification of patients with sepsis. The company intends to soon extend its clinical validation to other fields such as multiple sclerosis and other ailments.
Viva In Vitro avanza hacia la estratificación en atención y desarrollo de terapias personalizadas en sepsis, esclerosis múltiple y otras enfermedades inflamatorias o autoinmunes
The Scientific Advisory Committee is composed of Dr. Mihai Netea, as representative of Radboud University Medical Center (The Netherlands), Dr. Eduardo López Collazo, deputy director of Hospital Universitario de la Paz (Spain), and Dr. Rebecca Coll, of Queen’s University Belfast (UK).
In the dynamic realm of biotech startups, the judicious management of capital and the strategic application of retribution to capital techniques are pivotal for fostering growth and securing long-term sustainability.
Sensible Management of Retribution to Capital in Biotech Startups Read More »
Subscribe to VIVA Insights: The leading newsletter on inflammasomes and sepsis
Receive exclusive analysis, scientific breakthroughs and collaboration opportunities from our network of international partners and benchmarks.
